S'abonner

Cardiomyopathies et péricardite

JESFC 2023

Amylose

Publié le vendredi 13 janvier 2023

Modérateur(s) :

Antoine Fraix , Nicolas Piriou

Orateur(s) :

Grégoire Albenque , Jérôme Antonelli , Marine Pierre , Emmanuelle Berthelot , Anne-Laure Couturier , Marouane Elafrit , Elsa Ayo Bivigou , Salma Charfeddine , Thibaud Damy , Silvia Oghina

Dans la session

Emmanuelle Berthelot Heart Failure patients with cardiac amyloidosis are at higher risk of mortality and readmission after acute heart failure : a case control study fr...

Anne-Laure Couturier Is it possible to manage cardiac amyloidosis outside of reference centers ?

Elsa Ayo Bivigou Isolated chronic right heart failure due to tuberculosis sequelae: experience of the Libreville University Hospital Center

Salma Charfeddine The role of anti-oxidant markers in predicting the severity of chronic heart failure

Thibaud Damy Validation of Amylo-AFFECT, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloi...

Silvia Oghina Real-life evaluation of an algorithm for the diagnosis of cardiac amyloidosis

Grégoire Albenque Homozygote and heterozygote transthyretin p.Val142Ile (V122I) genetic variant: comparison of cardiac involvement, extracardiac manifestations and o...

Jérôme Antonelli Evolution and prognostic value of deformations parameters and myocardial work in Transthyretin Amyloid Cardiomyopathy

Marine Pierre Relationship between severity of HDP-99mTc myocardial uptake on bone scintigraphy (BS) and severity of cardiac involvement in transthyretine cardia...

Marouane Elafrit Clinical Characteristics and Outcomes of Adults With a History of Heart Failure in ambulatory patients with COVID 19

Thibaud Damy Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases